Mankind Pharma Ltd.

NSE: MANKIND | BSE: 543904 | ISIN: INE634S01028 | Industry: Pharmaceuticals
| Slowing Down Stock
2332.0000 -1.40 (-0.06%)
NSE Jun 30, 2025 09:48 AM
Volume: 28,106
 

2332.00
-0.06%
Motilal Oswal
Mankind Pharma (Mankind) delivered in-line revenue in 4QFY25; however, EBITDA/PAT came in 14%/12% below our estimates. Higher-than-expected spending on marketing and promotional activities affected the company’s 4Q performance.
Number of FII/FPI investors increased from 624 to 640 in Mar 2025 qtr.
More from Mankind Pharma Ltd.
Recommended